These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1466993)

  • 1. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG.
    Eichberg JW; Murthy KK; Ward RH; Prince AM
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1515. PubMed ID: 1466993
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
    Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
    Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS. Passive primate protection.
    Moore JP; Weiss RA
    Nature; 1991 Aug; 352(6334):376-7. PubMed ID: 1861715
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
    Cummins LM; Weinhold KJ; Matthews TJ; Langlois AJ; Perno CF; Condie RM; Allain JP
    Blood; 1991 Mar; 77(5):1111-7. PubMed ID: 1995097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S
    J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).
    Hurez V; Kaveri SV; Mouhoub A; Dietrich G; Mani JC; Klatzmann D; Kazatchkine MD
    Ther Immunol; 1994 Oct; 1(5):269-77. PubMed ID: 7584501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will sialylation change intravenous immunoglobulin therapy in the future?
    Käsermann F; Campbell IK
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):100-2. PubMed ID: 25546779
    [No Abstract]   [Full Text] [Related]  

  • 9. Passive immunization for the treatment and prevention of HIV infection.
    Karwowska S; Zolla-Pazner S
    Biotechnol Ther; 1991; 2(1-2):31-48. PubMed ID: 1845123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 11. Active and passive immunization against HIV type 1 infection in chimpanzees.
    Murthy KK; Cobb EK; Rouse SR; McClure HM; Payne JS; Salas MT; Michalek GR
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S271-6. PubMed ID: 9814955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies.
    Berger M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):144-5. PubMed ID: 25546798
    [No Abstract]   [Full Text] [Related]  

  • 13. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
    Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
    Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immune therapy for the treatment of HIV infections.
    Letvin NL; Chen ZW; Yamamoto H; Watanabe M
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1499. PubMed ID: 1466989
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of HIV-I IIIB infection in chimpanzees by CD4 immunoadhesin.
    Dis Markers; 1991; 9(6):339-41. PubMed ID: 1823314
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunization and challenge of chimpanzees with HIV-1.
    Fultz PN
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1517-9. PubMed ID: 1466994
    [No Abstract]   [Full Text] [Related]  

  • 17. Problems associated with passively transfused blood group alloantibodies.
    Garratty G
    Am J Clin Pathol; 1998 Jun; 109(6):769-77. PubMed ID: 9620038
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV vaccine development: lessons learned to date.
    Putney SD
    Biotechnol Ther; 1991; 2(1-2):1-7. PubMed ID: 1726960
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.
    Scharf O; Golding H; King LR; Eller N; Frazier D; Golding B; Scott DE
    J Virol; 2001 Jul; 75(14):6558-65. PubMed ID: 11413323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression.
    Marcelino JM; Nilsson C; Barroso H; Gomes P; Borrego P; Maltez F; Rosado L; Doroana M; Antunes F; Taveira N
    AIDS; 2008 Nov; 22(17):2257-65. PubMed ID: 18981765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.